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BACKGROUND. Heightened activity of the AKT signaling pathway is prominent in
malignant gliomas and has been suggested to play a role in treatment resistance.
Selective targeting of AKT, therefore, may increase chemosensitivity. Recently, a
novel class of AKT-selective inhibitors has been described, including SH-6, a phos-
phatidylinositol analogue.
METHODS. The effects of SH-6 on AKT signaling were tested in glioma cells, and the
putative role of AKT signaling in chemoresistance was tested by attenuating AKT
signaling pharmacologically and genetically. The initial characterization of SH-6
included treatment of glioma cells with increasing doses of SH-6 (0.30–30 mM) and
examining the effects on AKT signaling proteins by Western blot analyses and in
kinase assays with immunoprecipitated AKT1. Dose-response studies with SH-6
administered to glioma cell lines were performed using a luminescent cell-viability
assay (0.1–30 mM). Studies examining the effect of carmustine, either alone or in
combination with either the phosphatidylinositol 3-kinase inhibitor LY294002 or
SH-6, were performed by cell viability assays and clonogenic survival assays. The
effect of carmustine on AKT activity as a response to treatment also was examined.
Caspase assays were used to examine the potential role of apoptosis in SH-6/ car-
mustine -elicited cell death. Finally, the induction of a dominant-negative AKT1
transgene was used in combination with carmustine to demonstrate the role of
AKT1 in carmustine chemoresistance.
RESULTS. Serum-stimulated phosphorylation of AKT1 was inhibited by SH-6 at
doses 10 mM (>70% decrease in Threonine 308 and Serine 473 phosphorylation
of AKT1). In adenosine triphosphate assays, 72 hours of treatment with SH-6 led
to 50% lethal doses near 10 mM for 2 cell lines tested. SH-6 enhancement of
carmustine-mediated cell death led to synergistic increases in Caspase 3/Capsase
7 activity, implicating apoptosis as the cell death mechanism. In clonogenic
assays, SH-6 cotreatment with carmustine significantly decreased the number of
colonies at 10 mM (P < .05) compared with carmustine alone. No decrease was
observed in cells that were treated with SH-6 alone (10 mM). LY294002 (10 mM)
was also able to enhance the effects of carmustine significantly in both cell lines.
CONCLUSIONS. In the current study, the authors characterized the efficacy of a new
class of adjuvant chemotherapeutics that show promise in enhancing the efficacy
of standard chemotherapy regimens in gliomas. Cancer 2006;107:2446–54.
 2006 American Cancer Society.
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T he serine-threonine kinase AKT/protein kinase B is an oncogenicserine/threonine kinase with 3 known isotypes, each encoded by
a separate gene, AKT1, AKT2, AKT3 (protein kinase Ba, protein kinase
Bb, and protein kinase Bg.1 Recent studies in cancer research have
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implicated AKT isotypes in critical aspects of malig-
nant behavior, including the suppression of apoptosis,
the expression of genes critical to invasiveness, and
cell cycle progression.2–4 In gliomas, heightened AKT
activity has been demonstrated both in model cell
lines and in clinical tissue samples and has been
correlated with loss of function of the phosphatase
and tensin homolog (PTEN) tumor suppressor on
chromosome 10q23.5 Furthermore, in human glio-
blastoma tissues, AKT activity has been correlated
with poor overall survival.6
One consequence of deregulated AKT activity
that may underlie treatment failure derives from the
role of AKT in directly regulating target signaling pro-
teins through phosphorylation, including apoptotic
machinery like Caspase 9 and Bad.7,8 Furthermore,
because it has been found that AKT activity is deregu-
lated in tumors without PTEN deficiency, direct
targeting of AKT kinase with selective inhibitors may
be a more effective means of diminishing antiapopto-
tic signaling in chemoresistant glioma cells. Recent
studies have indicated that inhibition of AKT signaling
through PTEN restoration in PTEN mutant cell lines
can sensitize glioma cells to radiotherapy. The results
presented in the current study support a role for AKT
signaling in resistance to chemotherapy-induced cell
death in glioma by demonstrating an enhanced che-
mosensitivity of glioma cells to carmustine when they
are cotreated with SH-6, a novel phosphatidylinositide
analogue inhibitor of AKT kinases.7 Genetic evidence
using dominant-negative AKT1 is provided to support
further the notion that AKT signaling plays a signifi-
cant role in the chemoresistant phenotype in glioma.
MATERIALS AND METHODS
Cell Culture
U251MG cells were obtained from Dr. Geoffrey
Pilkington (Department of Neuropathology, University
of London). LN-z308 glioma cells were obtained from
Dr. Erwin van Meir (Department of Neurosurgery,
Winship Cancer Institute, Emory University). Cells
were cultured under identical growth conditions in
Dulbecco modified Eagle medium (DMEM) supple-
mented with 10% fetal bovine serum and 1% penicil-
lin-streptomycin solution at 378C in a humidified
incubator with 5% carbon dioxide (all materials from
Invitrogen, Gaithersburg, MD). Subculturing prior to
cell counting and seeding of cell for experiments was
performed by briefly washing cultures, incubation for
5 minutes using 0.25% trypsin-ethylenediamine tetra-
acetic acid (EDTA) solution (Invitrogen), centrifuging
cell suspensions at 330 g for 5 minutes to collect
cell pellets, and resuspending cells in fresh culture
medium prior to plating. Cell density counts were per-
formed using the Trypan Blue dye-exclusion method
and a Brightline Hemocytometer (Sigma Chemical
Company, St. Louis, MO).
Pharmacologic Inhibitors and Chemotherapeutic Agents
Chemical inhibitors that were selective for phosphati-
dylinositol 3 (PI3) kinase (LY294002) and AKT (SH-6)
were obtained from EMD Biosciences-Calbiochem
(San Diego, CA) and were reconstituted in sterile
dimethyl sulfoxide (DMSO) (Sigma Chemical Com-
pany) prior to freezing in aliquots at 208C. Each
aliquot was thawed only once, immediately prior to
use for experiments in vitro. Optimal concentrations
for achieving inhibition of PI3 kinases and AKT were
determined empirically in dose-response time-course
studies by analyzing phosphorylation states of down-
stream phosphorylation targets by Western blot (data
not shown). LY294002 was used at a concentration of
1 mM or 10 mM for the inhibition of PI3 kinase activity,
and SH-6 was used at a concentration of 10 mM for
the inhibition of AKT kinase activity. Growth media
with inhibitors at final concentrations were prepared
immediately prior to addition on cells.
Carmustine (Bristol-Myers Squibb or Sigma Chem-
ical Company) was prepared as a 50-mM stock solution
using sterile 100% ethanol according to the manufac-
turer’s suggested protocol and was used only once
because of the known instability of the compound.
Concentrations from 0.5 mM to 50 mM were used to
treat cells in vitro. Single and multiple administrations
were used, depending on the experimental design. Dur-
ing cell treatments, carmustine was added to the growth
medium and remained until fresh medium was added
or for the duration of the experiment. Experimental
conditions were performed in quadruplicate wells, and
each independent experiment was conducted 3 times.
Cell Lysate Preparation
Cell lysates were prepared in a modified RIPA buffer
(50 mM Tris-HCl [pH 7.4], 1% NP-40, 0.25% Na-
deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM phe-
nyl methyl sulfonyl fluoride, and 1 mM activated
sodium orthovanadate [all from Sigma Chemical
Company] supplemented with 1 Protease Inhibitor
Cocktail I, and 1 Phosphate Inhibitor Cocktail I
[EMD Biosciences–Calbiochem, San Diego, CA]).
Monolayers were rinsed briefly in phosphate-buffered
saline [pH 7.4] and from 0.4 mL to 1 mL chilled, mod-
ified RIPA was added per 107 cells. Cells were lysed for
30 minutes on ice with agitation, scraped with sterile
cell scrapers, and supernatant fluids were procured
after centrifugation for 10 minutes at 14,000 revolu-
tions per minute (rpm) in an Eppendorf 1513 C
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microcentrifuge at 48C. Lysates were assayed for pro-
tein concentration using the DC Protein Assay (Pierce
Chemical Company, Rockville, IL). For enzyme assays,
the same procedure was used, except that mamma-
lian protein extraction reagent was used as cell lysis
buffer (Pierce Chemical Company).
Immunoblotting
Total protein was investigated in 10-mg samples by
using Western blot analysis. Briefly, samples were
diluted in nanopure water in 4 NuPAGE sample
buffer with dithiothreitol as a reducing agent. Samples
were heated for 10 minutes at 708C and were loaded
directly into prepoured 4% to 20% Bis-Tris NuPAGE
gels along with prestained molecular weight stand-
ards (SeeBlue2; all reagents from Invitrogen). Electro-
phoresis was performed in 2-(N-morpholino)ethane-
sulfonic acid (MES) running buffer at a constant 200
volts for 50 minutes. Gels were rinsed briefly in ultra-
pure water, equilibrated for an additional 5 minutes
with the transfer buffer (40% methanol, NuPAGE
transfer buffer), and transferred to 0.2-mm pore nitro-
cellulose paper (Invitrogen) on ice at 260 mA constant
current for 2 to 3 hours. After that transfer, blots
were transferred briefly to Tris-buffered saline rinsing
buffer (TBST) (10 mM Tris, 150 mM NaCl, and 0.5%
Tween-20 [pH 8.0]), blocked for 1 hour at room tem-
perature in TBST supplemented with 5% nonfat dry
milk, and the primary antibody was applied overnight
at 48C on a rocking platform in fresh blocking buffer.
After 4 10-minute washes with TBST, species-specific,
horseradish peroxidase-conjugated secondary anti-
serum (1:5000 dilution; Rockland, Gilbertsville, PA)
was applied for 1.5 hour at room temperature with
agitation, the samples were washed for 1.5 hours
with frequent buffer changes, and they were treated
with enhanced chemiluminescence reagents (Amer-
sham Lifesciences, Piscataway, NJ) for 1 minute at
room temperature before they were subjected to auto-
radiographic film (Marsh BioProducts, Inc., Rochester,
NY). Film was developed on a Kodak X-Omat auto-
matic film processor; then, densitometry was per-
formed and analyzed with Imagequant software.
Antisera were used to detect AKT1 protein or phos-
phorylation state-specific AKT1 protein, and the ratio
of active AKT was computed after normalization to a
Cyclophilin-A loading control.
Immunopreciptation Kinase Assays
Total cell lysates were prepared as described above
after serum starvation for 16 hours and treatment for
15 minutes with 5% serum preincubated with SH-6,
LY294002, or control solvent solution. Equivalent
amounts of lysate per sample (200 mg per condition)
were incubated overnight with 2 mg agarose bead-
conjugated monoclonal anti-AKT1 antibody (clone
2H10; Cell Signaling Technologies, Beverly, MA) at 48C.
After 3 10-minute washes with TBST, beads were
collected by centrifugation, and the remaining buffer
was discarded. AKT1 immunoprecipitates were resus-
pended in kinase assay buffer (Cell Signaling Tech-
nologies), according to the manufacturer’s suggestion,
along with 3000 mCi 32P-g adenosine triphosphate
(ATP) and GSK3b substrate peptide and were incu-
bated for 30 minutes at room temperature. Scintilla-
tion counting was performed on triplicate samples
applied to phosphocellulose paper after washing
3 times in 0.75% phosphoric acid. Alternately, reaction
immunoprecipitates were boiled in 2  Laemmli
sample buffer for 5 minutes and subjected to Western
blot analysis to assess AKT1 pull down and for the
detection of phosphorylated GSK3b peptide with
rabbit polyclonal antisera specific to the Serine-9 site
(Cell Signaling Technologies).
Cell Growth and Viability Assays
Cell growth and viability studies were performed using
the Cell Titer-Glo luminescent ATP assay (Promega
Inc., Madison, WI). Glioma cells were added to white,
opaque-walled, sterile, 96-well plates at a concentra-
tion of 500 cells per 100 mL medium per well in 6
wells per condition and were allowed to settle over-
night (for 16 hours) in 10% serum-containing DMEM.
The next day, medium was replaced with 5% serum-
supplemented DMEM with the following additives:
Preincubation for 1 hour was performed with the AKT
inhibitor SH-6 (10 mM) or the PI3 kinase inhibitor
LY294002 (10 mM) versus equimolar, sterile, cell-
culture tested DMSO (Sigma-Aldrich, St. Louis, MO)
as a solvent control. Next, media were replaced with
fresh inhibitor in the presence or absence of carmus-
tine (10 mM or 50 mM) Viable cell numbers were then
determined by adding 100 mL Cell-Glo lysis reagent,
incubating at room temperature for 2 minutes with
manual agitation, incubating for an additional 8 min-
utes on a rotating platform at 48C, equilibrating at
room temperature for 15 minutes, and luminescence
detected using a BMG Lumistar luminescent plate
reader (Cell-Titer Glo Reagents [Promega Inc.]; Lumi-
star Luminescent Plate Reader [BMG LabTechnologies
GMBH, Durham, NC]). Mean relative light units were
calculated for replicates within each condition and
were compared using Student t tests with the signifi-
cance threshold set at 95% confidence (P < .05).
Clonogenic Survival Assays in Vitro
Clonogenic assays were performed in 5% medium in
6-well plates by plating 200 cells per well (U251MG
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cells) or 300 cells per well (LN-z308 cells) based on
the determined plating efficiency of each cell line,
such that equivalent numbers of clones were achieved
in the untreated control wells. Glioma cells were
plated in triplicate wells in the presence or absence of
inhibitors and/or carmustine. After cell plating, cell
plates were left for 8 days in the incubator under
standard conditions. Cells were washed briefly with
PBS, fixed for 30 minutes in 100% methanol, stained
with Geimsa stain, and destained in distilled water.
Quantification of clones was performed in replicate
wells for each test condition using a counting pen,
and cell numbers of each clone were verified by visual
inspection using phase-contrast microscopy. Indivi-
dual clones were defined as islands of at least 25
contiguous cells. Assays were repeated for 3 inde-
pendent experiments.
Caspase 3 Activity Assay
Caspase 3 activity was measured by using a lumines-
cent peptide cleavage assay (Lumi-Glo Caspase-Glo
3/7 Assay; Promega Inc.) under the following parame-
ters. Glioma cells were plated at 500 cells per 100 mL
medium per well in clear, white, opaque-walled,
96-well plates and were allowed to settle for 24 hours.
Cells were pretreated for 1 hour with vehicle alone
(DMSO) or with varying concentrations of AKT inhi-
bitor (0–10 mM SH-6; EMD Biosciences). After prein-
cubation with inhibitor, cells were treated with
carmustine as indicated above and were incubated for
3 days. Medium was removed, and cells were assayed
for caspase activity by using the manufacturer’s proto-
col. Assay conditions were performed in triplicate,
and 3 independent trials were performed for each assay.
Transfection of AKT Combinational DNAs
LN-z308 glioma cells were a gift from Dr. Erwin Van
Meir (Winship Cancer Institute, Emory University and
were transfected stably with the pTET-On vector
incorporating the puromycin-resistance gene (also a
gift from Dr. Erwin Van Meir). LN-Z-Tet-on cells were
maintained in 1 mg/mL puromycin, prior to trans-
fection in 6-well plates with 1.2 mg pTRE-AC-AKT
(myristoylated, constitutively active, mutant AKT1),
pTRE-DN-AKT (dominant-negative AKT1), or empty
vector control per 4  105 cells by using 3 mL Lipofec-
tamine 2000 (Invitrogen). Transfections were per-
formed in 0.5 mL 2% serum per well in 6-well plates
for 4 hours followed by the addition of antibiotic-free
10% DMEM for an additional 20 hours before cells
were replated in selection medium with 1 mg/mL
puromycin and 300 mg/mL G418 (Invitrogen) or for
use in transient expression experiments. Expression
of AKT transgene variants was achieved by the addi-
tion of 2 mg/mL doxycycline to the growth medium.
AKT expression and consequential protein activation
were monitored by analyzing protein extracts that
were prepared 24 hours after the addition of doxycy-
cline (72 hours posttransfection). Expression levels of
AKT1 protein and Myc-tagged transgene expression
were measured by analyzing Western blots with speci-
fic antisera at a dilution of 1:2000, as described
(mouse monoclonal anti-AKT1, clone 2H10; and
Mouse monoclonal anti Myc-Tag clone; Cell Signaling
Technologies).
RESULTS
Pharmacologic Inhibition of AKT
Glioma cells were examined for phosphorylation levels
of AKT under normal growth conditions. Selected cell
lines were chosen to demonstrate the efficacy of the
phosphatidylinositide analogue SH-6, which has been
shown in preliminary studies to prevent AKT phos-
phorylation.7 Western blot analyses using antisera
specific for total AKT1 or phosphorylation state-speci-
fic AKT demonstrated a dose-dependent reduction in
detectable phosphorylated AKT relative the detectable
amounts of total AKT protein in repeated assays of
extracts supplemented with phosphatase inhibitors
(Fig. 1A-C). First, to demonstrate the induction of
AKT1 phosphorylation, 5% fetal calf serum was used
to stimulate serum-starved glioma cells for 15 min-
utes to generate an increase in AKT phosphorylation.
Figure 1A shows that both U251MG and LN-z308
glioma cells showed a pronounced AKT activation in
cell lysates, as detected by Western blot analysis using
phosphorylation-specific antisera. A >2-fold increase
in the active AKT1/total AKT1 ratio was detected in
U251MG cells after stimulation (Fig. 1A). Under the
same conditions, incubation of glioma cells with 1–30
mM SH-6 caused a significant 60% to 90% abrogation
of AKT phosphorylation at doses of 10 mM or greater,
as detected at the Threonine 308-AKT and Serine 473
positions with phosphorylation site-specific antisera.
To assay the effects of SH-6 on AKT1 activity directly,
cell lysates were pretreated for 1 hour with increasing
concentrations of SH-6 or the PI3 kinase inhibitor
LY294002. Immunoprecipitated AKT1 stimulated with
serum for 15 minutes showed a 5-fold increase in
phosphotransferase activity toward GSK3b peptide
compared with serum-starved controls. Preincubation
with SH-6 or LY294002 effectively suppressed the level
of phosphotransferase activity in a dose-dependent
manner, as shown in Figure 1C. The peptide substrate
also was detected by Western blot analysis with
phosphorylation-specific antisera, and the levels nor-
malized to detectable amounts of AKT1 in each immu-
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noprecipitate (Fig. 1B). In either format, SH-6 doses
10 mM were necessary to achieve 70% suppression
of phosphotransferase activity as detected in immu-
noprecipitates. Therefore, the dose of 10 mM SH-6
was used in subsequent experiments to suppress AKT
activity.
Effects of SH-6 on Glioma Cell Survival in Vitro
To examine the effect of AKT inhibitor treatment on
the viability of glioma cells, luminescence-based ATP
assays were used. U251MG and LN-z308 cells were
treated for 72 hours with increasing doses of SH-6 or
equimolar DMSO (solvent control), and viability was
determined after 3 days of treatment. Mean relative
light units from replicate detected values were con-
verted to percent control and plotted with standard
deviation of the means included (Fig. 2). The lethal
doses to 50% (LD50s) for the 2 cell lines tested were
approximately 10 mM, as indicated in Figure 2 (dotted
horizontal line),. Significant decreases in cell survival
were observed as low as 1 mM in LN-z308 cells and
3 mM in U251MG cells.
Inhibition of AKT by SH-6 Decreases Clonogenic
Survival of Glioma Cells
It is believed that the clonogenic survival of cancer
cells reflects tumor aggressiveness. Because AKT sig-
naling plays an important role in cell survival, we
tested the response of glioma cells to carmustine,
which is a commonly administered chemotherapy
agent in gliomas. Figure 3 shows that U251MG glio-
mas cells that were treated with carmustine responded
with an increase in detectable phosphorylated AKT,
indicating that the cellular response to carmustine
toxicity involves enhanced AKTactivity. Next, U251MG
and LN-z308 glioma cells were plated in clonogenic
assays, left overnight for 16 hours, then pretreated
with SH-6 or LY294002 at 10 mM, DMSO solvent con-
trol and at 0 mM, 10 mM, or 50 mM carmustine for
FIGURE 1. The attenuation of AKT signaling by the AKT inhibitor SH-6
(a phosphatidylinositol analogue) is illustrated. (A) Serum stimulation induces
activation of AKT in 2 glioma cell lines (U251MG and LN-z308), as detected by
Western blot (WB) analysis of 10 mg total protein. Rabbit polyclonal antisera
raised against phosphorylated Thr308-AKT (pThr308AKT), phosphorylated
Ser473-AKT (pSer473AKT), and anti-AKT1 (AKT1) (all at 1:2000 dilution; Cell
Signaling Technologies) were used to detect protein levels of active and total
AKT1. S* indicates dimethyl sulfoxide (DMSO) control; , without serum sti-
mulation; þ, stimulated with 5% serum. (B) Serum treatment stimulated the
activation of AKT activity toward GSK3b peptide-bearing the Ser9 AKT phospho-
rylation site after 15 minutes of stimulation (5% serum vs. serum-free medium,
SH-6, or the phosphatidylinositol 3-kinase [PI3] inhibitor LY294002). Phospho-
rylated peptide was detected by immunoblot analysis after 30 minutes of incu-
bation with AKT1 immunoprecipitates from serum stimulated cells that were
subjected to SH-6 or LY294002 at the indicated dose for 60 minutes. IP indi-
cates immunoprecipitation; MAb, monoclonal antibody; CPM, 32P counts per mi-
nute. (C) Preadministration of SH-6 to serum-starved glioma cells for 30
minutes diminished AKT1 kinase activity against GSK3 in a concentration-de-
pendent fashion. The PI3 inhibitor LY294002 also attenuated this activity in a
dose-dependent manner at both Thr308 and Ser473 sites in the regulatory do-
main of AKT1. Representative results for U251MG are shown (B,C). S indicates
DMSO solvent control (0 mM in B and C); B, background CPM signal (in C); PC,
peptide input control (without AKT).
~
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1 week. Each condition was performed in triplicate
for 3 separate independent trials. Cells were fixed in
methanol, stained, and counted as described above.
Figure 4 shows that, in LN-z308 cells, a significant
decrease (69%) in cell death was achieved with 10 mM
SH-6 coadministration compared with carmustine
alone (P ¼ .0013). Repeated assays of U251MG cells
showed an additional 31.4% mean decrease in cell vi-
ability compared with carmustine alone (P ¼ .021;
data not shown). It is noteworthy that little effect was
observed on colony numbers with SH-6 treatment
alone in either cell line with this assay.
Induction of Caspase Activity after Coadministration
of carmustine and SH-6
To begin an examination of the mechanism by which
AKT inhibitor augments carmustine-mediated cell
death, direct activity of the effector Caspases 3 and 7
was assayed by using a luminescent peptide substrate-
cleavage assay. Lysis of cells in assay buffer supple-
mented with Caspase 3/Caspase 7-specific peptide
substrate was performed using a carmustine dose of
10 mM and the dose of SH-6 that was used in the car-
mustine experiments (10 mM). In LNz-308 cells, which
were chosen because they exhibited the greatest sen-
sitivity to both carmustine and SH-6, we observed
that treatment with 10 mM SH-6 alone was able to
induce a significant decrease in viability, which we
assayed by detecting the ATP content per well at
36 hours, proportional to the number of viable cells
present (Fig. 2). In the caspase activity assay (Fig. 5),
carmustine alone at 10 mM was able to induce a mod-
est but detectable increase in caspase activity (2.7-
fold) compared with solvent control at 36 hours. Treat-
ment with SH-6 alone similarly was able to induce
caspase activity at 10 mM (3.8-fold). When carmu-
FIGURE 4. Cotreatment of glioma cells with carmustine (BCNU) and AKT
signaling inhibitors enhanced cell kill. Glioma cells were treated for 1 week in
clonogenic growth assays with BCNU (10 mM), the selective AKT inhibitor
SH-6 (10 mM), or the selective phosphatidylinositol 3-kinase inhibitor
LY294002 (10 mM) both alone and in combination. A comparison of the mean
colony number was performed by using a Student t test for unpaired data.
Significance is indicated by P values <.05 (single asterisk) and <.01 (double
asterisks).
FIGURE 2. This chart illustrates dose-dependent survival response in glioma
cell lines that were treated with the phosphatidylinositol analogue AKT inhibi-
tor SH-6. Cell lines were treated for 72 hours with SH-6, and differences in
cell survival were measured by using a luminescence based assay for ATP
content. (Diamonds, U251MG cells; Squares, LN-z308 cells. Bars indicate
standard deviation of the mean. Data represent the mean of 3 independent
experiments. The dotted line that intercepts with each curve indicates the
lethal dose to 50%, as determined in this assay.
FIGURE 3. These blots illustrate AKT activity in glioma cells that were
treated with carmustine (BCNU). Cells from the glioma cell line U251MG
were treated for increasing periods over 24 hours (h) with 10 mM BCNU,
and phosphorylated AKT (p-AKT) was assessed by Western blot analysis.
P-Ser473AKT indicates phosphorylated Ser473-AKT; P-AKT ratio, ratio between
p-AKT and AKT; ET, ethanol solvent control.
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stine was coadministered with SH-6, a greater than
additive increase in caspase activity was detected at
doses 10 mM.
Decreased Clonogenic Growth of Glioma Cells
Treated with Dominant-Negative Mutant AKT1
To examine further the impact of AKT signaling on
chemoresistant phenotype in gliomas, a tetracycline-
inducible dominant-negative mutant transgene for
human AKT1 was used, because this isotype of AKT
has been implicated the greatest in glioma malig-
nancy. In LN-z308 glioma cells stably cotransfected
with the pTet-On vector and either a modified empty
pTRE response vector or bearing the dominant-nega-
tive Myc-tagged AKT1 transgene, the induction of
transgene expression was monitored over the course
of 72 hours. Figure 6 shows that robust transgene
expression was detected at 48 hours and 72 house
after the addition of doxicycline (2 mg/mL) to the
culture medium by using an Myc-tag antibody in
protein lysates and Western blot analysis. No expres-
sion was observed in the parental cell line or in the
empty vector controls. These stable transfectants
were used in clonogenic assays under the influence of
doxicycline.
Dominant-negative AKT1 transgene expression
led to a significant decrease in mean colony numbers
(P ¼ .02; t test), as shown in Figure 7. The administra-
tion of increasing dose of carmustine led to decreases
in the mean number of colonies that were character-
istic of previous assays (see Fig. 4). SH-6 was used as
an additional treatment in this assay to determine
whether additional cell kill could be achieved by using
both genetic and pharmacologic methods of perturb-
ing AKT function simultaneously. In both parental
LN-z308 cells and empty vector controls, a small but
significant difference in cell viability was observed
with the inclusion of SH-6 in the media compared
with no SH-6, indicating an enhancement in cell kill
FIGURE 7. Induction of DN-AKT1 in stably Tet-On transfected LN-z308
glioma cells enhanced sensitivity to carmustine (BCNU) in the clonogenic
assay. Clonogenic survival assays were conducted with LN-z308 cells that
were cotransfected stably with the empty pTRE/pTetOn vector or with the DN-
AKT1-pTRE/PTet-On vector, incorporating the dominant-negative AKT1 mutant
transgene, and were compared with parental LN-z308 cells in the presence of
doxycycline (2 mg/mL) to maintain transgene expression. Sensitivity to BCNU
treatment was examined over 8 days in vitro. Colonies were counted after
methanol fixation and Geimsa staining. Statistical comparisons of mean colony
numbers between all conditions were performed using a Student t test for
unpaired data, with resulting P values of <.05 (single asterisk) and <.01
(double asterisks).
FIGURE 6. These blots illustrate the time course of induction of Myc-tagged
(Myc-Tag) DN-AKT1 transgene after doxycycline treatment. Cell lysates were
prepared at 48 hours (h) and 72 hours after doxycycline treatment (2 mg/mL)
and assayed by Western blot analysis (10 mg total protein). Anti-Myc-Tag
monoclonal antibody was used to detect DN-AKT1 (1:1000 dilution; Cell Sig-
naling Technologies). Cyclophilin A protein detection was included as a loading
control (1:3000 dilution; rabbit polyclonal antisera; Upstate Biotechnology,
Inc.). P-Ser473 indicates phosphorylated Ser473-AKT; C, control; VC, vector
control; KDa, kilodaltons.
FIGURE 5. AKT inhibition by the selective AKT inhibitor SH-6 enhanced
carmustine (BCNU)-mediated Caspase 3 activity. An intermediate dose of
10 mM BCNU was used to determine whether AKT inhibition with SH-6 treat-
ment (10 mM) increased caspase activity after alkylating chemotherapy. Lumi-
nescent adenosine triphosphate-based Caspase 3/Caspase 7 assay (Promega
Inc.). RLU indicates relative light units. *P < .05, **P < .01, ***P < .001.
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(P < .05 in all experiments). However, no significant
difference was observed under conditions in which
DN-AKT1 and SH-6 were present simultaneously, sug-
gesting that 1 method of AKT perturbation may pre-
vent perturbation by a separate mechanism with a
similar mode of action.
DISCUSSION
The role of heightened AKT signaling in cancer has
been well documented. In malignant gliomas, this
increase has been attributed primarily to loss of func-
tion of the PTEN tumor suppressor and constitutive
activation of growth factor-receptor tyrosine kinase
signaling pathways. In the current study, we attempted
to target AKT signaling directly, by both pharmaco-
logic and genetic means, to assess whether AKT activ-
ity plays a significant role in suppression of apoptotic
cell death during the administration of standard
chemotherapy in gliomas.9,10
First, we tested the ability of a novel phosphati-
dylinositol analogue inhibitor, SH-6, to diminish AKT
activation. SH-6 was characterized previously, and we
observed that it was selective for AKT isotypes, parti-
cularly AKT1 isoenzyme, which has been identified as
the most commonly overactive isozyme in astrocytic
gliomas (our own data).6 Using Western blot assays,
we demonstrated that pretreatment of 2 glioma cell
lines for 30 minutes with SH-6 at doses of 10 mM led
to reductions >60% in active AKT1 under the influ-
ence of serum stimulation, as evidenced by detection
with phosphorylation-specific antisera. At both the
Serine473 and Threonine308 phosphorylation sites,
which are the 2 major phosphorylation sites located
within the regulatory domain, significant reduction
was detected after treatment. To assess the effects of
pharmacologic inhibition of AKT on tumor cell via-
bility, glioma cell lines were treated with increasing
doses of SH-6 compared with solvent control
(DMSO). The LD50 values for SH-6 in 2 glioma cell
lines were near 10 mM for a 3 day treatment period.
Cotreatment of gliomas with carmustine and SH-
6 or with the PI3 kinase inhibitor LY294002 enhanced
carmustine -mediated cell death in clonogenic sur-
vival assays (Figs. 3 and 4). The significant decreases
in glioma cell survival after carmustine treatment and
the augmentation observed in AKT phosphorylation
after carmustine suggest that part of the response of
glioma cells to carmustine treatment involves an AKT-
dependent mechanism. It is noteworthy that, with
this assay, repeated assay of SH-6 alone at 10 mM did
not decrease clonogenicity significantly in these cell
lines, which was unexpected. LY294002 (10 mM) was
potent in its ability to diminish clonogenicity under
the same conditions. This finding suggests that either
another putative AKT-independent mechanism or a
separate target of SH-6 may be involved with the sup-
pression of cell death under the influence of carmus-
tine treatment. Therefore, additional studies will
focus on refining our understanding of the molecular
events that underlie the response to carmustine in
these cell lines.
By using the expression of a dominant-negative
mutant transgene (DN-AKT1) (Fig. 6) to perturb AKT1
function, a decrease in glioma cell survival was
achieved, which also enhanced carmustine -mediated
cell death compared with controls (Fig. 7). In our
hands, additional SH-6 treatment did not enhance
cell death further beyond that achieved with DN-
AKT1 expression and carmustine, despite the ability
of SH-6 to enhance cell death in parental and vector
control cells that were treated with carmustine. The
differing effects of AKT interference by SH-6 and DN-
AKT1 in clonogenic survival may provide important
clues about the specific modes of action of these 2
targeting mechanisms during carmustine -mediated
cell death and, when they are understood better, may
lead to more efficient methods of enhancing che-
motherapeutic efficacy by AKT targeting.
To investigate further the precise mechanism of
cell death observed in glioma cells treated with 10 mM
SH-6 in the presence of 10 mM carmustine, we used
caspase activity assays. Treatment with either 10 mM
carmustine or 10 mM SH-6 alone significantly in-
creased the activity level of effector Caspase 3 and
Caspase 7, as detected in this assay (P ¼ .035, and
P ¼ .021, respectively, compared with solvent controls;
Student t test for unpaired data). Concomitant treat-
ment of glioma cells with carmustine and SH-6 led to
a greater than additive increase in caspase activity at
10 mM. Comparison of mean values with carmustine
treatment alone demonstrated that the elevated
response was significant (Student t test for unpaired
data). The enhancement of caspase activity by SH-6
and the greater than additive enhancement of car-
mustine -mediated caspase activity suggest that at
least part of the impact of SH-6 on glioma cells
derives from an increase in apoptotic sensitivity in
response to carmustine. This effect may derive from a
release of the suppression of proapoptotic factors
upstream of Caspase 3/Caspase 7.
The results of this study suggest that AKT inhibi-
tion can lead to enhanced sensitivity to alkylating
chemotherapy agents, and our findings suggest that
this occurs by relieving the inhibition of apoptotic
cellular response in gliomas, a tumor that is notorious
for its clinical intractability. In other cancers, the role
of AKT1 and AKT2 in antiapoptotic signaling also is
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apparent.8,10 The combined effect of using pharmaco-
logic inhibitors of AKT and standard chemotherapies
appears to be in line with an improved clinical out-
come both in vitro and in reported studies of animal
models.11,12 This is encouraging for further develop-
ment of AKT inhibitors for clinical use in patients with
cancer.
It has been demonstrated that compounds like
SH-6 that target the PH domain of AKT prevent AKT
recruitment to signaling complexes in the plasma
membrane.7,13 However, no data have been published
to date that address the effect of direct AKT inhibition
on carmustine sensitivity, nor have there been detailed
studies published on AKT isotype-specific efficacy in
vivo. Such studies will be required to justify the fur-
ther development of these promising novel adjuvant
therapies. The significance of AKT signaling in glioma
biology has been reinforced by several recent studies
in which transgenic mice bearing conditionally over-
expressed AKT1 and mutant Ras gave rise to more
malignant tumors than Ras over-expressing mice, and
have histologic features more akin to glioblastoma
versus lower grade glioma.14–16 Such reports underline
the importance of AKT as a factor in the malignancy
of gliomas and support the rationale for further test-
ing of AKT inhibitors in vivo and, eventually, in
human patients.
REFERENCES
1. Bayascas JR, Alessi DR. Regulation of Akt/PKB Ser473pho-
sphorylation. Mol Cell. 2005;18:143–145.
2. Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell pro-
liferation, survival and insulin responses? J Cell Sci. 2001;
114(Pt 16):2903–2910.
3. Liang J, Zubovitz J, Petrocelli T, et al. PKB/Akt phosphoryl-
ates p27, impairs nuclear import of p27 and opposes p27-
mediated G1 arrest. Nat Med. 2002;8:1153–1160.
4. Arboleda MJ, Lyons JF, Kabbinavar FF, et al. Overexpression
of AKT2/protein kinase Bbeta leads to up-regulation of
beta1 integrins, increased invasion, and metastasis of hu-
man breast and ovarian cancer cells. Cancer Res. 2003;63:
196–206.
5. Fan X, Aalto Y, Sanko SG, Knuutila S, Klatzmann D, Castre-
sana JS. Genetic profile, PTEN mutation and therapeutic
role of PTEN in glioblastomas. Int J Oncol. 2002;21:1141–
1150.
6. Ermoian RP, Furniss CS, Lamborn KR, et al. Dysregulation
of PTEN and protein kinase B is associated with glioma his-
tology and patient survival. Clin Cancer Res. 2002;8:1100–
1106.
7. Kozikowski AP, Sun H, Brognard J, Dennis PA. Novel PI
analogues selectively block activation of the pro-survival
serine/threonine kinase Akt. J Am Chem Soc. 2003;125:1144–
1145.
8. Gagnon V, Mathieu I, Sexton E, Leblanc K, Asselin E. AKT
involvement in cisplatin chemoresistance of human uterine
cancer cells. Gynecol Oncol. 2004;94:785–795.
9. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV. The
Akt/PKB pathway: molecular target for cancer drug discov-
ery. Oncogene. 2005;24:7482–492.
10. Westfall SD, Skinner MK. Inhibition of phosphatidylinositol
3-kinase sensitizes ovarian cancer cells to carboplatin and
allows adjunct chemotherapy treatment. Mol Cancer Ther.
2005;4:1764–1771.
11. Thomas S, Shah G. Calcitonin induces apoptosis resistance
in prostate cancer cell lines against cytotoxic drugs via
the Akt/survivin pathway. Cancer Biol Ther. 2005;4:1226–
1233.
12. Delord JP, Allal C, Canal M, et al. Selective inhibition of
HER2 inhibits AKT signal transduction and prolongs dis-
ease-free survival in a micrometastasis model of ovarian
carcinoma. Ann Oncol. 2005;16:1889–1897.
13. Caron RW, Yacoub A, Li M, et al. Activated forms of H-RAS
and K-RAS differentially regulate membrane association of
PI3K, PDK-1, and AKT and the effect of therapeutic kinase
inhibitors on cell survival. Mol Cancer Ther. 2005;4:257–
270.
14. Hu X, Pandolfi PP, Li Y, Koutcher JA, Rosenblum M, Holland
EC. mTOR promotes survival and astrocytic characteristics
induced by PTEN/AKT signaling in glioblastoma. Neoplasia.
2005;7:356–368.
15. Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN,
Holland EC. Ink4a-Arf loss cooperates with KRas activation
in astrocytes and neural progenitors to generate glioblasto-
mas of various morphologies depending on activated Akt.
Cancer Res. 2002;62:5551–5558.
16. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE,
Fuller GN. Combined activation of Ras and Akt in neural
progenitors induces glioblastoma formation in mice. Nat
Genet. 2000;25:55–57.
2454 CANCER November 15, 2006 / Volume 107 / Number 10
